International Patent: T CELL-TARGETED LIPID NANOPARTICLES (CTLNPS) FOR DELIVERY OF SIRNA AND USE IN TREATING AUTOIMMUNE DISORDERS

GENEVA, Aug. 21 -- GENERATION BIO CO. filed a patent application (US2026/015189) for “T CELL-TARGETED LIPID NANOPARTICLES (CTLNPS) FOR DELIVERY OF SIRNA AND USE IN TREATING AUTOIMMUNE DISORDERS”. With publication no. WO/2026/174149, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 47/69

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....